Wearable biosensor technology developer Biolinq announced today that it named Richard Yang as its new CEO.
San Diego-based Biolinq, which develops biosensor platforms to measure continuous glucose for managing diabetes, among other clinical conditions, said in a news release that Yang is a veteran of more than 20 years with time spent at top-tier medical device companies.
Biolinq co-founder Jared Tangney, who previously served as CEO, will now take on the role of president & chief operating officer as Yang takes over the CEO position.
“We’ve had the pleasure of getting to know Rich well over the past several years and we’re thrilled to welcome him on board to lead Biolinq to the next stage of our development,” Tangney said in the release. “Throughout his career, Rich has repeatedly helped lead companies with groundbreaking technology to category-defining status.”
Yang previously worked with MiniMed insulin pumps before working in Medtronic’s diabetes segment. Most recently, he spent almost a decade at Dexcom in an executive leadership role.
“Biolinq was a natural draw for me, particularly due to its innovative approach to dermal sensing and profound microneedle array technology that has the potential to significantly transform the user experience,” Yang said. “It’s an honor to help build upon the vision of the company’s founders and I look forward to advancing new technologies that will serve the diabetes community and beyond.”